AstraZeneca PLC (NASDAQ:AZN – Free Report) – Investment analysts at Zacks Research decreased their Q4 2024 earnings per share estimates for shares of AstraZeneca in a research note issued to investors on Wednesday, August 7th. Zacks Research analyst R. Department now expects that the company will earn $0.99 per share for the quarter, down from their prior estimate of $1.08. The consensus estimate for AstraZeneca’s current full-year earnings is $4.05 per share. Zacks Research also issued estimates for AstraZeneca’s Q2 2025 earnings at $1.10 EPS, Q1 2026 earnings at $1.16 EPS and Q2 2026 earnings at $1.21 EPS.
AstraZeneca (NASDAQ:AZN – Get Free Report) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. AstraZeneca’s revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.08 EPS.
Read Our Latest Research Report on AstraZeneca
AstraZeneca Trading Down 0.2 %
AZN traded down $0.16 during midday trading on Thursday, hitting $81.19. 3,078,360 shares of the company were exchanged, compared to its average volume of 5,345,006. The firm has a market capitalization of $251.73 billion, a P/E ratio of 39.80, a P/E/G ratio of 1.50 and a beta of 0.45. AstraZeneca has a 1-year low of $60.47 and a 1-year high of $82.01. The firm’s 50 day moving average price is $79.00 and its 200-day moving average price is $72.76. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.
AstraZeneca Cuts Dividend
The company also recently announced a Semi-Annual dividend, which will be paid on Monday, September 9th. Investors of record on Friday, August 9th will be given a $0.49 dividend. This represents a yield of 1.8%. The ex-dividend date is Friday, August 9th. AstraZeneca’s payout ratio is 48.04%.
Institutional Trading of AstraZeneca
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the 2nd quarter worth approximately $26,000. Able Wealth Management LLC purchased a new position in shares of AstraZeneca in the 4th quarter worth approximately $27,000. Pathway Financial Advisers LLC purchased a new position in shares of AstraZeneca in the 1st quarter worth approximately $29,000. Hobbs Group Advisors LLC purchased a new position in shares of AstraZeneca in the 2nd quarter worth approximately $35,000. Finally, Pin Oak Investment Advisors Inc. boosted its stake in shares of AstraZeneca by 468.4% in the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after buying an additional 370 shares during the last quarter. 20.35% of the stock is owned by institutional investors.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
See Also
- Five stocks we like better than AstraZeneca
- What is a buyback in stocks? A comprehensive guide for investors
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 8/5 – 8/9
- How to Choose Top Rated Stocks
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.